Rocket Pharmaceuticals (RCKT) Non-Current Deffered Revenue (2017 - 2018)
Rocket Pharmaceuticals (RCKT) posted Non-Current Deffered Revenue of $457000.0 for Q4 2018, up 4.34% sequentially from $438000.0 in Q3 2018, and up 327.1% YoY from $107000.0 in Q4 2017.
Powered by 
Analysis
Rocket Pharmaceuticals (RCKT) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Rocket Pharmaceuticals has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $457000.0 in Q4 2018.
- Quarterly Non-Current Deffered Revenue rose 327.1% year-over-year to $457000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $457000.0 (up 327.1% YoY) and the FY2018 annual result came in at $457000.0, up 327.1% from the prior year.
- Non-Current Deffered Revenue advanced to $457000.0 in Q4 2018 per RCKT's latest filing, from $438000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $598000.0 in Q1 2018 and troughed at $107000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Rocket Pharmaceuticals | 437.27 Mn | 437.27 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 457,000.00 |
| Sep 30, 2018 | 438,000.00 |
| Jun 30, 2018 | 510,000.00 |
| Mar 31, 2018 | 598,000.00 |
| Dec 31, 2017 | 107,000.00 |